« Return to News | Drug Sponsors

Maxygen board to dissolve, liquidate company

Wednesday, June 5, 2013 01:42 PM

The board of biopharmaceutical company Maxygen has approved the liquidation and dissolution of the company, subject to shareholder approval, and plans to distribute all available cash to its shareholders after making reasonable provision for known and potential liabilities and other obligations of the company. Maxygen currently estimates the initial liquidating distribution to stockholders will be between $68.2 million and $69.6 million, or $2.45 to $2.50 per share.

James Sulat will resign as the chief executive officer and chief financial officer and from the board on June 30. The board has appointed Isaac Stein, executive chairman of the board, to act as the company's CEO and CFO.

 “Through the estimated liquidating distributions and the company's prior distributions and stock repurchases, Maxygen will have returned approximately $320 million in cash and property to the company's shareholders since December 2009,” said Stein.

Maxygen also intends to delist its common stock from the Nasdaq Global Market, close its stock transfer books, discontinue recording transfers of shares of its stock and seek relief from certain of its reporting obligations under the Securities Exchange Act of 1934, as amended.

If, prior to its dissolution, Maxygen receives an offer  that will provide superior value to shareholders compared to the value of the estimated distributions, the plan of dissolution could be abandoned.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.